FDA grants 12 year exclusivity to Flublok Influenza vaccine- Protein Sciences
The FDA is granting exclusivity to Flublok Influenza vaccine, from Protein Sciences, for a period of 12 years. Flublok is the first vaccine awarded this very important status, demonstrating Flublok as a unique and game changing influenza vaccine.
The US FDA determination of regulatory exclusivity means that no product similar to Flublok can be approved by US FDA before January 16, 2025. Flublok, the world's first recombinant protein-based vaccine for the prevention of seasonal influenza disease, was approved by FDA in January 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins